ATL 101 - Alizyme

Drug Profile

ATL 101 - Alizyme

Alternative Names: ATL101 - Alizyme; AZM 128

Latest Information Update: 19 Oct 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alizyme; Rowett Research Institute
  • Class Growth factors
  • Mechanism of Action Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mucositis

Most Recent Events

  • 19 Oct 2001 Discontinued-Preclinical for Mucositis in United Kingdom (Unknown route)
  • 03 Apr 2000 Alizyme has been granted exclusive rights to manufacturing technology for ALT 101
  • 30 Oct 1998 Alizyme is discussing out-licensing with potential partners
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top